Awards logo feature image

Three Navy Yard Companies Recognized for Work in Life Sciences

Awards-logo (1)

Congratulations are in order for three Navy Yard life companies that received industry awards at an event held in Miami January 19. The Phacilitate Advanced Therapies Awards ceremony recognized and celebrated the progress in the advanced therapies field.

The three Navy Yard companies recognized for their contributions to the life sciences sector were:

  • Adaptimmune: The Patient Advocacy Award (Corporate): Adaptimmune received this award for their work around patient advocacy, putting the patient first in all decisions made while being dedicated to spreading awareness of the potential that cell and gene therapy has.
  • Iovance Biotherapeutics, Inc.: Biotech Innovation Award: Iovance received this  award for their  demonstration of innovation in the cell and gene therapy industry as well as their significant potential for impact on patients in the future.
  • WuXi Advanced Therapies: Manufacturing Tech Disruptor of the Year: WuXi received this award for their innovative new technologies to help simplify and improve the manufacturing process.

Life Sciences Ecosystem at the Navy Yard

Currently, the Navy Yard features a powerful combination of clinical healthcare, advanced life sciences R&D, and cell and gene therapy production. The Navy Yard is uniquely suited to attract and support life sciences both locally and internationally. With its proximity to the innovation and talent pool in University City and the surrounding region, the Navy Yard is an alluring option for companies that have outgrown their space in urban submarkets but are still looking leverage the nearby innovation and talent pool.

Adaptimmune copy Iovance award copy wuxi copy


Coriell Life Sciences Research Finds Precision Medicine Has Reached a Global Tipping Point for Adoption


Big news coming from Coriell Life Sciences. Their newly published research, authored by leaders at the company, reveals that the time is finally right for healthcare systems, employers, and governments to establish genome-informed clinical decision-making as the new standard of care.

“The stage is set for leaders around the world to change healthcare as we know it,” says co-author Scott Megill, President and CEO of Coriell Life Sciences. “Studies have shown that using genetic information to provide more targeted therapeutic care significantly improves patient outcomes and reduces the overall cost of healthcare. This is especially true for pharmacogenomics (PGx), which uses an individual’s DNA to determine if medications are likely to be unsafe or ineffective for them specifically. We’re now entering a new age where barriers have transformed into boons for PGx-enabled precision medicine.”

The research paper, published by Cambridge University Press, examines the maturation of critical factors required for the use of clinical genetics at scale, including:

  • Clinical utility
  • Laboratory technology
  • User acceptance
  • Implementation models
  • Economic value

Coriell Life Sciences is headquartered in the Navy Yard is a precision medicine genetics company using genetic science and research to improve lives, reduce healthcare costs, and simplify decision-making for their customers throughout the United States and around the world.

You can read the full story on the Coriell Life Sciences website.



Navy Yard Skills Initiative Connected More Than 60 Philadelphians to Jobs in 2022

Since its inception in August 2020, more than 120 Philadelphians have participated in 8 cohorts of PIDC’s Navy Yard Skills Initiative (NYSI) training programs, but 2022 was by far the most successful year of NYSI in connecting Philadelphians to meaningful employment in growing industries within the Navy Yard.

NYSI training programs are designed for individuals who have been disconnected from the workforce or who have limited professional experience to strengthen the skills and abilities that employers need. Through a partnership with University City District’s West Philadelphia Skills Initiative (WPSI), NYSI recruits for a collaborative professional development program to train Philadelphia residents for permanent, full-time, quality-wage careers.

2022 by the Numbers

  • Cohorts: 6
  • Participants served: 93
  • Graduates connected with full-time quality jobs: 62 + 13 participants in the externship at Iovance Biotherapeutics for the Biomedical Technician Training Program (January 2023 – March 2023)
  • Placement rate for graduates: 88% of those who graduated from programs, including the 13 Iovance externships, were placed in full-time positions. This placement rate will increase after Jefferson graduates are hired.
  • Average starting wage: $17.37/hour
Date Employer Position Starting Wage Participants Served Participants Graduated Job Offers
Jan-22 Tastykake Production Associate $17.17 16 12 12
Mar-22 Philly Shipyard Inc. Apprentice $17.13 17 16 15
Jun-22 Tastykake Production Associate $14.65 16 12 12
Sep-22 Iovance Biotherapeutics Aseptic Manufacturing Technician $23.00 17 13 current participants 13 offered externship opportunities
Sep-22 Philly Shipyard Inc. Apprentice $17.13 9 6 6
Oct-22 Jefferson Health Patient Registrar $15.15 18 16 9 (job placement + interviewing in-progress)

Biomedical Technician Training Program: Aseptic Manufacturing Technician

In August, five organizations partnered to design a new biotech training program to connect Philadelphians with quality jobs in the region’s rapidly growing life sciences sector.

The Wistar Institute, West Philadelphia Skills Initiative, Iovance Biotherapeutics, PIDC, and The Chamber of Commerce for Greater Philadelphia collaborated to create a new workforce development training model to connect biotech jobs with a wider range of Philadelphians, including residents from disadvantaged communities. In a field that often requires PhDs or master’s degrees for most roles, the program – “Biomedical Technician Training Program: Aseptic Manufacturing” – creates opportunities for Philadelphians with at least a high school equivalency. The initiative is one way the region is working together to meet the talent needs in its rapidly growing cell and gene therapy sector.

Read more about the 22-week program here.

2022 BioBuzz Workforce Champion of the Year Award

In December, the Biomedical Technician Training Program was awarded Workforce Champion of the Year in the 3rd Annual 2022 BioBuzz Awards. The Workforce Champion Award recognizes the program or organization that has made a measurable contribution to enhancing the biotech workforce within the region.

You can read more about the award here and watch the acceptance video below.

NYSI participants in the Biomedical Technician Training Program: Aseptic Manufacturing Technician cohort.

NYSI participants in the Biomedical Technician Training Program: Aseptic Manufacturing Technician cohort.

NYSI participants are briefed in a Philly Shipyard, Inc. cohort.

NYSI participants are briefed in a Philly Shipyard, Inc. cohort.

Graduates of the NYSI Tastkake cohort pose for a picture.

Graduates of the NYSI Tastkake cohort pose for a picture.

Participants of the NYSI Jefferson Health cohort attend a training session.

Participants of the NYSI Jefferson Health cohort attend a training session.

Graduates of a NYSI Philly Shipyard, Inc. cohort pose with Congresswoman Mary Gay Scanlon as she awards a $525,000 check to the NYSI.

Graduates of a NYSI Philly Shipyard, Inc. cohort pose with Congresswoman Mary Gay Scanlon as she awards a $525,000 check to the NYSI.


BioBuzz blog feature image

Navy Yard Skills Initiative Program Named Workforce Champion


BioBuzz Workforce Champion Award goes to Wistar’s New Biomedical Technician Training Program for Adults 

A collaborative program with West Philadelphia Skills Initiative, Iovance Biotherapeutics, and PIDC focuses on training adults for jobs in the specialized life science sector.

 PHILADELPHIA — (DECEMBER 14, 2022) — The Wistar Institute Biomedical Technician Training (BTT) Program was awarded Workforce Champion of the Year in the 3rd Annual 2022 BioBuzz Awards. The program is a collaborative that includes The Wistar Institute, West Philadelphia Skills Initiative, Iovance Biotherapeutics, PIDC, and others. The award, based on votes from individuals throughout the community, celebrates the outstanding life science institutes, companies, and people that make up the Philadelphia and BioHealth Capital Regions. The program, modeled on Wistar’s successful BTT Program for community college students, focuses on an underserved adult population – adults with a GED or high school diploma.

“This Program was conceived of—by Philadelphians—and for Philadelphians,” said Kristy Shuda McGuire, Ph.D., Wistar dean of biomedical studies. “What better way to support our growing workforce than with Philadelphia residents trained in sought after, specialized skills. The newest iteration of our BTT Program is focused on meeting demands of local biotechnology companies for a diverse and skilled workforce.”

The more than 400 applicants support the fact that there is a strong interest among Philly’s adult population to explore this career opportunity. From that applicant pool, 18 participants were chosen and are currently learning in Wistar’s Training Lab. West Philadelphia Skills Initiative led recruitment, selection, and professional development programming.

“The development of this unique program required thoughtful collaboration from key partners ranging from University City, to Philadelphia Works, to the Navy Yard, and more,” said Cait Garozzo, executive director of the West Philadelphia Skills Initiative. “We are tremendously pleased for the recognition from BioBuzz for what we feel is a truly innovative workforce program.”

Funding was provided by Philadelphia Works, grants from the Pennsylvania Department of Labor and Industry PAsmart program, GSK, and Justamere Foundation. BTT Program graduates who successfully complete the training qualify for technician positions at Iovance Biotherapeutics. The Program prepares participants for skilled positions that involve maintaining sterile labs, assembling sterile products, stocking supplies, and documenting processes of biomedical manufacturing – a rapidly growing area in Philadelphia.

“Iovance is excited to help introduce a wider, diverse range of Philadelphians to new technical skills and career options in biotech manufacturing,” said Jamie Crawford, vice president of Iovance Cell Therapy Center (iCTC) Manufacturing at Iovance Biotherapeutics. “We hope this new program can serve as a model of inclusivity within the biotech workforce, to fill the growing demand for technicians in the region.”

“This award truly reflects how meaningful, strategic partnerships can support positive change and provide quality opportunities to individuals and communities that previously lacked access,” said Kate McNamara, PIDC’s senior vice president, Navy Yard. “It’s very exciting that the Navy Yard and PIDC are involved in this partnership and are part of workforce solutions for a rapidly growing industry.”


The Wistar Institute, the first independent nonprofit biomedical research institute in the United States, marshals the talents of an international team of outstanding scientists through a highly enabled culture of biomedical collaboration and innovation, to solve some of the world’s most challenging and important problems in the field of cancer, immunology, and infectious diseases, and produce groundbreaking advances in world health. Consistent with a pioneering legacy of leadership in not-for-profit biomedical research and a track record of life-saving contributions in immunology and cell biology, Wistar scientists pursue novel and courageous research paths to life science discovery, and to accelerate the impact of early-stage discoveries by shortening the path from bench to bedside.

The West Philadelphia Skills Initiative (WPSI) is one of the nation’s most successful workforce development organizations. For 10 years, WPSI has solidified its role as one of the highest performing workforce intermediaries in the country by building customized talent solutions that bridge the divide between unemployed Philadelphians seeking opportunity and employers seeking talent. WPSI focuses on professional development and career coaching for adults.

Iovance Biotherapeutics (NASDAQ: IOVA) aims to be the global leader in innovating, developing and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells in each patient. Located in Philadelphia, PA, our Iovance Cell Therapy Center (iCTC) is the first centralized and scalable manufacturing facility dedicated to producing TIL therapies for patients with solid tumors. Our lead late-stage TIL product candidate, lifileucel for metastatic melanoma, has the potential to become the first approved one-time cell therapy for a solid tumor cancer. For more information, please visit

PIDC is Philadelphia’s public-private economic development corporation. Since acquiring the 1,200-acre site from the federal government in 2000, PIDC has been the master developer and site operator of the Navy Yard. PIDC’s mission—to spur investment, support business growth, and facilitate developments that create jobs, revitalize neighborhoods, and drive growth to every corner of Philadelphia—strongly informs its strategy for the Navy Yard, where the focus is on building a cohesive community that fosters employment, innovation, and production. PIDC manages all aspects of the property’s management and development, including master planning, leasing, property management, infrastructure development, utility operation, and structuring development transactions.

Delegate visit feature image

The Navy Yard Welcomes Delegation of Leaders from India Focusing on Biomedical Entrepreneurship, Technology, and Innovation

A delegation of biomedical leaders from India visited the Navy Yard on October 7 as part of a larger visit to understand biomedical entrepreneurship, technology, and innovation in the Philadelphia region.

During the visit, Navy Yard leadership briefed the group on the growing life sciences ecosystem, sustainability efforts, and future development plans at the Navy Yard. The group also enjoyed a guided tour to learn about the past, present, and future of the Navy Yard.

The Philadelphia tour was organized by Citizen Diplomacy International. Citizen Diplomacy International is a nonprofit organization that empowers its citizens to represent the city and the United States through person-to-person diplomacy. They showcase the best of Philadelphia and make global connections for Philadelphians; inspiring Philadelphia to be a global city and be globally recognized. Each year, its Citizen Diplomats volunteers welcome nearly 1,300 international visitors to Philadelphia on high school exchange programs, professional exchange programs, and trade missions.

Citizen Diplomacy International worked with the U.S. Department of State-sponsored exchange program called the International Visitor Leadership Program (IVLP).  The IVLP is the U.S. Department of State’s premier professional exchange program. Through short-term visits to the United States, current and emerging foreign leaders in a variety of fields experience this country firsthand and cultivate lasting relationships with their American counterparts. Each year nearly 5,000 International Visitors come to the U.S. on the International Visitor Leadership Program (IVLP). More than 200,000 International Visitors have engaged with Americans through the IVLP, including more than 500 current or former Chiefs of State or Heads of Government.


Dylan Langley, Navy Yard Director of Leasing & Development, briefs a delegation of biomedical leaders from India on the life sciences ecosystem at the Navy Yard. The group visited Philadelphia to better understand biomedical entrepreneurship, technology, and innovation in the region.

Dylan Langley, Navy Yard Director of Leasing & Development, briefs a delegation of biomedical leaders from India on the life sciences ecosystem at the Navy Yard. The group visited Philadelphia to better understand biomedical entrepreneurship, technology, and innovation in the region.

Coriell Blog featured image copy

Coriell Life Sciences Earns Second PBMI Excellence Award for Cost Containment

Congratulations to Coriell Life Sciences on earning their second Pharmacy Benefit Management Institute (PBMI) Excellence Award for Cost Containment om honor of their Corigen® Medication Safety Program, which eliminates a root cause of healthcare waste—medications that are harming people instead of helping them—and in turn reduces needless healthcare costs in a major way.

Coriell Life Sciences is headquartered in the Navy Yard is a precision medicine genetics company using genetic science and research to improve lives, reduce healthcare costs, and simplify decision-making for their customers throughout the United States and around the world.

Coriell Award Icon

From the Coriell Life Sciences award announcement:

“This award speaks to the fact that Corigen is not only the most comprehensive pharmacogenomics (PGx) offering on the market, but also one of the most impactful,” says Jeffrey A. Shaman, Chief Science Officer at Coriell Life Sciences, who was also selected as a speaker for the event. “When individuals and their physicians are empowered to avoid medications that are ineffective or unsafe based on their DNA and other personal factors, the measurable economic, clinical, and humanistic benefits are all quite significant.”

These benefits are illustrated in a peer-reviewed study published in the Journal of Personalized Medicine. The research examined the real-world outcomes of a Corigen implementation with a group of 5,288 Medicare Advantage members over 32 months. Findings included:

  • Lower rates of healthcare resource utilization. Among participants, inpatient visits decreased by 14.9%, Emergency Department visits decreased by 6.8%, and outpatient visits decreased by 1.9%.
  • Millions of dollars in cost savings. Driven by a decrease in Emergency Department visits and inpatient hospitalizations, direct medical charges were reduced by approximately $7,000 per member for a cumulative savings of more than $37 million over 32 months.

Payers everywhere are struggling with the rising costs of care. By eliminating a root cause of healthcare waste—medications that are harming people instead of helping them—we can reduce these costs in a major way,” notes Dr. Shaman.

Corigen, which was also honored with the PBMI Excellence Award for Cost Containment in 2020, is a turnkey PGx solution for employers, health plans, pharmacy benefit managers, and other large populations. It includes everything from population analytics (identifying high-risk, likely-to-benefit members) to member engagement, DNA testing, pharmacist consultation, physician engagement, and reporting.

Learn more about the Corigen Medication Safety Program here.


Groundbreaking ceremony with Ensemble/Mosaic, Oxford, PIDC, and Councilmember Kenyatta Johnson

Ensemble/Mosaic and Oxford Properties Group Break Ground on Speculative R & D Lab Building

Ensemble/Mosaic, a joint venture between Ensemble Real Estate Investments and Mosaic Development Partners, and Oxford Properties Group (“Oxford”), a leading global real estate investor, asset manager and business builder, have broken ground on 1201 Normandy Place, a speculative 137,000 square foot R & D lab building at the Navy Yard in Philadelphia. The project represents the first new development initiated as part of Ensemble/Mosaic and Oxford’s recently executed strategic partnership.

“1201 Normandy represents a significant milestone for the Navy Yard, our new partnership with Mosaic and Oxford, and Philadelphia’s life sciences community,” said Mark Seltzer, Senior Vice President, Development-East at Ensemble. “The building will play a critical role in the life science ecosystem of the campus by creating space for smaller gene and cell therapy users and providing a place to grow as their business evolves towards commercialization and manufacturing. This is the right product, at the right time in the right location, and we are already experiencing strong interest.”

1201 Normandy Place

“The Navy Yard is a critical asset to Philadelphia’s life science community,” said Philadelphia City Councilmember Kenyatta Johnson, whose Second Council District includes the Navy Yard.  “The development of this new 137,000 square foot laboratory and office building here at 1201 Normandy Place is the first development by Ensemble Real Estate Investments and Mosaic Development Partners.  The lab building is tailored specifically to gene and cell therapy companies and will further drive economic growth at the Navy Yard, which is a major economic engine of our city.”

1201 Normandy Place is the first speculative multi-tenant R & D lab building at the Navy Yard. The building was designed in consultation with CRB, a leading lab designer, to be the most sophisticated lab building in the region optimized for cell and gene therapy R & D companies, while maintaining the flexibility to accommodate all users. The modern four-story facility will feature 137,000 square feet of highly customizable lab space and will be able to support life science customers ranging from 5,000-35,000 square feet per floor. Special user-specific considerations include 15’-16’ floor-to-floor ceiling heights, predetermined GMP space, structural integrity that minimizes vibration and two loading docks. The robust utility and safety features include a central plant HVAC system with water cooled chillers, customizable electrical output and layout as well as built-in emergency power. Occupants will also have access to collaborative workspace, an outdoor balcony on each floor and a ground level cafe. The building is projected to achieve LEED Gold Certification.  CBRE is leading the marketing  efforts for 1201 Normandy Place.

“Today’s groundbreaking builds on our partnership’s considerable momentum, as we take a major step towards delivering a world-class life science innovation hub at the heart of the Navy Yard,” said Chad Remis, Executive Vice President, North America at Oxford. “The speed at which we’ve advanced this project is testament to the relationship between Oxford and Ensemble/Mosaic—in both our vision for the project, as well as our shared conviction in Philadelphia and its continued emergence as one of the premier global biopharma markets.”

1201 Normandy will allow smaller-scale gene and cell therapy companies to take space in the Navy Yard’s thriving life science community. Currently, it is home to many world-class and well-established gene and cell therapy firms including Iovance Biotherapeutics, Adaptimmune Therapeutics PLC, WuXi Advanced Therapies Coriell Life Sciences, Vinta Bio, Inc., and is the regional headquarters of Ben Franklin Technology Partners.

“The depth of our collective development experience, this unparalleled location and our ability to move quickly are tremendous advantages for us,” said Greg Reaves, CEO and Co-Owner, Mosaic. “We designed 1201 Normandy to be at the leading edge of R & D lab space, offering customers superior utility packages and safety features. This building will truly be transformational to the life science community and the Navy Yard as a whole.”

Groundbreaking ceremony with Ensemble/Mosaic, Oxford, PIDC, and Councilmember Kenyatta Johnson

Ensemble/Mosaic and Oxford

Recently, Ensemble/Mosaic and Oxford Properties Group entered into a strategic partnership which will, over time, own and develop up to 3 million square feet of life science properties at the Navy Yard in Philadelphia. The agreement includes Oxford’s investment in five existing life science assets owned by Ensemble Real Estate Investments, and Ensemble/Mosaic’s two initial life science properties, of which 1201 Normandy is the first. In addition, Oxford will look to partner in all future life science projects on sites controlled by Ensemble/Mosaic at the Navy Yard. The deal represented Oxford’s first investment in Philadelphia and further expands the firm’s extensive life science portfolio, which includes over US$2 billion of investment activity in North America since the start of 2021.

PIDC Senior Vice President Kate McNamara considers the Ensemble/Mosaic and Oxford partnership a boon that will help continue to grow the ecosystem of the Navy Yard.

“Developing a speculative life science building that can house multiple users illustrates the strength of the market in Philadelphia and the strong interest by companies to take advantage of all the Navy Yard has to offer,” said McNamara. “This is a big milestone for the Navy Yard, Ensemble/Mosaic, Oxford, and PIDC that will create a landscape for lifesaving work and job opportunities for all Philadelphians. We’re at an important intersection of what the city needs and what will benefit the world, and it’s an exciting moment.”

Ensemble/Mosaic at the Navy Yard

In 2020, Ensemble/Mosaic announced plans for its US$2.6 billion development plan, designed to further establish the Navy Yard as a vibrant and inclusive mixed-use community. Through its agreement with PIDC—Philadelphia’s public-private economic development corporation, which oversees all management and development of the Navy Yard, the joint venture plans for approximately 3,000 residential units and more than 3 million square feet of life science manufacturing, R & D, office, hotels, makerspace and retail space when complete. In addition to 1201 Normandy and 333 Rouse, the $400+ million first phase includes the development a three-building residential complex with ground floor retail (including an AVE in partnership with Korman Communities) and a signature adaptive reuse hotel.

Sumit Verna, Iovance iCTC site head, at the ribbon cutting ceremony. He is joined by Fred Vogt, Iovance CEO, Governor Tom Wolf, and Mayor Jim Kenney.

Iovance Biotherapeutics Celebrates Grand Opening of Iovance Cell Therapy Center (iCTC)

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL, and peripheral-blood lymphocyte, PBL), is celebrating the official opening of the Iovance Cell Therapy Center (iCTC). The iCTC, located at the Philadelphia Navy Yard, is the first centralized, scalable, state-of-the-art manufacturing facility dedicated to producing TIL cell therapies for patients with solid tumor cancers. The current capacity is expected to meet potential demand for thousands of patients per year with multiple types of cancers, including clinical trial patients and future commercial patients.

Frederick Vogt, Ph.D., J.D., Interim President and Chief Executive Officer of Iovance, stated, “Since Iovance was founded, we have been dedicated to advancing novel cell therapies for patients with solid tumor cancers. As the hub of cell and gene therapy and the home of leading hospitals and academic centers, Philadelphia became the city of choice for our internal manufacturing. A little over two years after breaking ground, iCTC is now one of the largest cell therapy manufacturing facilities in the world and may ultimately house hundreds of employees. We now have the capacity to supply broad access to TIL therapies for patients. I believe that the important ecosystem within Cellicon Valley will continue to contribute to our advancements to pioneer a new class of treatment for cancer.”

A ribbon cutting event celebrates the opening with special guests including Pennsylvania Governor Tom Wolf, Philadelphia Mayor Jim Kenney, and other government officials and collaborators within Cellicon Valley. Patients, caregivers, and patient advocacy organizations, including Melanoma Research Foundation (MRF), Melanoma Research Alliance (MRA) and the Society for Gynecological Oncology’s Foundation for Women’s Cancer cut the ribbon on behalf of everyone who is currently fighting cancer, and in memory of those who lost their battles with cancer.

Sumit Verna, Iovance iCTC site head, at the ribbon cutting ceremony. He is joined by Fred Vogt, Iovance CEO, Governor Tom Wolf, and Mayor Jim Kenney.

“The iCTC is a symbol of significant innovation and opportunity for the commonwealth as hundreds of new, high-paying jobs will ultimately be created at this facility,” said Governor Tom Wolf. “Iovance has already made a positive impact on the region and worked with a great sense of urgency to complete construction and begin initial manufacturing for patients with cancer.”

“The iCTC represents a new model in cell therapy manufacturing and bolsters Philadelphia’s reputation as a leading location for technology, innovation, and life sciences,” said City of Philadelphia Mayor Jim Kenney. “Iovance is a great example of what companies from around the country and the world may accomplish in establishing Philadelphia as the place to attract talent and grow their business.”

Located at 300 Rouse Boulevard and with approximately 136,000 square feet of space, the iCTC is among the largest cell therapy manufacturing facilities today. The iCTC is currently supplying Iovance clinical studies, and commercial manufacturing is expected to begin after initial product approval. The iCTC was developed and built by Gattuso Development Partners, LLC and the design and construction management firm CRB. Financial incentives were provided by the Commonwealth of Pennsylvania, the City of Philadelphia, and PIDC, including the site’s designation as a Keystone Opportunity Improvement Zone, which allows incentives for business development.

About Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics aims to improve patient care by making T cell-based immunotherapies broadly accessible for the treatment of patients with solid tumors and blood cancers. Tumor infiltrating lymphocyte (TIL) therapy uses a patient’s own immune cells to attack cancer. TIL cells are extracted from a patient’s own tumor tissue, expanded through a proprietary process, and infused back into the patient. Upon infusion, TIL reach tumor tissue, where they attack cancer cells. The company has completed dosing in pivotal programs in patients with metastatic melanoma and cervical cancer. In addition, the company’s TIL therapy is being investigated in a registration-supporting study for the treatment of patients with locally advanced, recurrent or metastatic non-small cell lung cancer. Clinical studies are also underway to evaluate TIL in earlier stage cancers in combination with currently approved treatments, and to investigate Iovance peripheral blood lymphocyte (PBL) T cell therapy for blood cancers. For more information, please visit

Forward-Looking Statements

Certain matters discussed in this press release are “forward-looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). All such written or oral statements made in this press release, other than statements of historical fact, are forward-looking statements and are intended to be covered by the safe harbor for forward-looking statements provided by the PSLRA. Without limiting the foregoing, we may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “forecast,” “guidance,” “outlook,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors, many of which are outside of our control, that may cause actual results, levels of activity, performance, achievements and developments to be materially different from those expressed in or implied by these forward-looking statements. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled “Risk Factors” in our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, and include, but are not limited to, the following substantial known and unknown risks and uncertainties inherent in our business: the effects of the COVID-19 pandemic; risks related to the timing of and our ability to successfully develop, submit, obtain and maintain U.S. Food and Drug Administration (“FDA”) or other regulatory authority approval of, or other action with respect to, our product candidates, and our ability to successfully commercialize any product candidates for which we obtain FDA approval; preliminary and interim clinical results, which may include efficacy and safety results, from ongoing clinical trials or cohorts may not be reflected in the final analyses of our ongoing clinical trials or subgroups within these trials or in other prior trials or cohorts; the risk that enrollment may need to be adjusted for our trials and cohorts within those trials based on FDA and other regulatory agency input; the new version of the protocol which further defines the patient population to include more advanced patients in our cervical cancer trial may have an adverse effect on the results reported to date; the risk that we may be required to conduct additional clinical trials or modify ongoing or future clinical trials based on feedback from the FDA or other regulatory authorities; the risk that our interpretation of the results of our clinical trials or communications with the FDA may differ from the interpretation of such results or communications by the FDA; the acceptance by the market of our product candidates and their potential reimbursement by payors, if approved; our ability or inability to manufacture our therapies using third party manufacturers or our own facility may adversely affect our potential commercial launch; the results of clinical trials with collaborators using different manufacturing processes may not be reflected in our sponsored trials; the risk that unanticipated expenses may decrease our estimated cash balances and forecasts and increase our estimated capital requirements; and other factors, including general economic conditions and regulatory developments, not within our control.


Iovance Biotherapeutics, Inc:
Sara Pellegrino, IRC
Vice President, Investor Relations & Public Relations
650-260-7120 ext. 264

Solebury Trout:
Zara Lockshin

Redevelopment of historic Building 624: Historic Core pedestrian plaza flanked by artisan makerspaces for authentic local retail. Credit: Groundswell

PIDC and Ensemble/Mosaic Execute Navy Yard Development Agreement, Launching $2.5 Billion Development Plan

Media Contacts: Robbie Tarpley Raffish, a.s.a.p.r. (for Ensemble/Mosaic) 410-430-9705; Jessica Calter, PIDC, 215-496-8161

PIDC, Philadelphia’s public-private economic development corporation and master developer of the Philadelphia Navy Yard, in partnership with Ensemble Real Estate Investments and Mosaic Development Partners, today announced the execution of an agreement which provides Ensemble/Mosaic with the exclusive development rights for 109 acres at the Navy Yard and launches a $2.5 billion development plan that will create thousands of construction and permanent jobs.

The $400 million first phase includes development of two advanced life sciences buildings followed by significant residential and hospitality initiatives. Ensemble/Mosaic will construct a +/-100,000 square foot speculative laboratory and office development at 1201 Normandy Place with anticipated delivery by the close of 2022. The partners will concurrently market 333 Rouse Boulevard, which can accommodate a 120,000 square foot build-to-suit facility, for opportunities with cGMP (current Good Manufacturing Practice) manufacturers. Upon completion of these buildings the Navy Yard will eclipse one million square feet of life sciences space.

“Execution of the development agreement with Ensemble and Mosaic and commencement of their initial life sciences projects will launch the next exciting chapter of development at the Navy Yard.  Expanding this vibrant life sciences hub will bring high quality jobs to the Navy Yard, support growing companies in the advanced life sciences sector, and contribute to development of this dynamic campus that is already home to 15,000 employees,” said Kate McNamara, Senior Vice President, PIDC. “Equally exciting, our agreement includes one of the most intentional and inclusive economic opportunity initiatives in the history of this city.”

Ensemble Owned and Ensemble Mosaic Development Rights at the Navy Yard

Mosaic Development Partners is a Philadelphia based firm which specializes in commercial and mixed-use development. Since 2012, Mosaic has secured and invested more than $120 million in Philadelphia neighborhoods, bringing quality retail, commercial, recreational, and residential space to communities of color, along with hundreds of construction and full-time jobs.

Smallwood-Lewis said, “For the last eight years, Mosaic has built profitably with community and cultural sensitivity in mind, and this project is in many ways a culmination of our experience to date. The next phase of development Navy Yard represents a unique opportunity to build community and add density, while making the most of the waterfront access and incredible open spaces that have already grown in use and importance during this past year. It is an exciting time, and we are pleased to partner with PIDC and Ensemble in this effort.”

The agreement, which was initially announced last July, will guide the growth and expansion of the former military base and will further establish the Navy Yard as a vibrant and inclusive mixed-use community. Ensemble/Mosaic ultimately envisions approximately 3,000 residential units and nearly three million square feet of life science manufacturing, R&D, office, hotels, makerspace and retail space when complete.

Phase One of Ensemble/Mosaic development at the Navy Yard

Expanding Life Science Capacity is a Top Priority

The building at 1201 Normandy Place is designed by DIGSAU, an award-winning contemporary architecture firm, in collaboration with CRB, a global architecture and engineering firm, which together aims to set a new standard for innovation. Philadelphia-based DIGSAU has designed five buildings in the Navy Yard. CRB is a preeminent designer for life science manufacturing and laboratory environments.

The four-story facility targeting LEED Gold certification is conceived with flexibility at the forefront. Its 30,000 square foot floor plates with 16’ floor-to-floor heights will provide lab and clinical manufacturing-ready environments for ATMP (advanced therapy medicinal products) and life science companies. Spaces between 5,000 to 100,000 square feet will be available, maximizing both efficiency and optionality for the company’s operations.

“Located minutes from University City, the home of cell and gene therapy research, the Navy Yard is a critical component in the growth of life science companies in the region. It will allow companies to incubate, commercialize and manufacture within 15 minutes of each other and an international airport,” said Seltzer. “Our new buildings will create much-needed inventory for the incredible demand for space in this sector.”

The preliminary concept for 333 Rouse Boulevard is a 120,000 square foot facility providing office, laboratory space, cGMP manufacturing, warehousing and conditioned indoor mechanical space for plant and critical utilities. The manufacturing area will support interior ceiling heights up to 16’ and provide floor heights designed to facilitate cGMP manufacturing with walkable cleanroom ceiling systems.

The project provides for a balance of short-term efficiency and long-term flexibility, making it an ideal home to life sciences companies seeking immediate functionality and the ability to grow in place. This project is being designed by DIGSAU and IPS-Integrated Projects Services, LLC, a locally founded company that ranks as one of the top biologics, cell and gene therapy design firms in the world solely dedicated to designing, constructing and qualifying cGMP facilities.

Diversity, Equity, and Inclusion Strategy Drives Development

A key aspect of the vision of this dynamic and vibrant campus is that it provides opportunities for all Philadelphians. To that end, the partners are committed to deploying a robust and novel approach to diversity, equity, and inclusion in all elements of the 109 acres in the agreement.

“From the teams we assemble to design and build the buildings, to the projects and people who will occupy them, the Navy Yard will be a more inclusive place for all,” said Reaves. “Our collective goal is to create a national model that combines institutional development and inclusive strategies in new and exciting ways.”

This holistic inclusion strategy provides tremendous opportunities for minority- and women-owned business enterprise (M/WBE) participation. This will include diverse equity ownership with an innovative crowd-funding component, substantial M/WBE participation in construction and operations, inclusion of local and M/WBE small businesses in retail and makerspace opportunities, a paid internship program with Cheyney University, and the allocation of a share of net income to a charitable foundation that will create new opportunities for young people in Philadelphia. Additional details will be released at another time.

“These and other initiatives will attract female and minority students in high school and college from across the region and the country who are interested in pursuing a career in commercial real estate, construction, architecture and design. It’s not just about planning and building for now, it’s about doing so for the future, too,” Reaves added.


In September 2019, PIDC put out a call for prospective partners through a Request for Qualifications (RFQ). PIDC received more than 35 responses to the RFQ in December 2019. Based on the RFQ criteria, five highly experienced teams were shortlisted and invited to submit full proposals in response to a comprehensive Request for Proposals (RFP). After detailed review and evaluation of the proposals and virtual team interviews with an Advisory Panel, PIDC selected the Ensemble/Mosaic co-development team in July 2020.

In January 2021, PIDC and Ensemble/Mosaic released a Request for Proposals (RFP) opportunity for large-scale comprehensive master planning at the Navy Yard. The team sought proposals from qualified, experienced, diverse, and inclusive planning, design, and engineering firms to develop and deliver a comprehensive master plan. The 2021 Navy Yard Master Plan Update will establish a dynamic, cohesive, and achievable placemaking vision and development framework as the Navy Yard embarks on its next phase of expansion and growth. An announcement about the master plan firm will be made in the coming weeks.

PIDC retained JLL in early 2019 to advise in this selection of a development partner. JLL supported PIDC throughout the RFQ and RFP processes, and assisted PIDC with development agreement negotiations.

Click for additional information about PIDC, the Navy Yard, Ensemble, or Mosaic.

300 Rouse Boulevard, view from Central Green. Credit: DIGSAU

Iovance Biotherapeutics Announces New Facility at the Navy Yard to Support U.S. Production of Tumor Infiltrating Lymphocyte Cell Therapy Products

Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it has entered into a lease agreement to build an approximately 136,000 square foot commercial-scale production facility at the Philadelphia Navy Yard for commercial and clinical production of autologous TIL products, including its candidate lifileucel. Read more